ImmuneOnco Biopharma, founded in June of 2015 in Zhangjiang High-Tech Park of Shanghai, China, is a clinical-stage biopharmaceutical company dedicated to development and commercialization of innovative cancer immunotherapy. The company has established several solid platforms harnessing both innate and adaptive immune cells. Macrophages play a critical role in fighting cancer through phagocytosis followed by presenting of tumor antigen to T cell. However cancer cells are smart and can always find a way to evade the surveillance, such as by over-expressing immune checkpoints including CD47.
ImmuneOnco takes the advantage of the IP-protected SIRPa-domain to develop the mAb-Trap format by which several bispecific recombinant antibody-receptor proteins has been developed that simultaneously targeting CD47 and other tumor targets such as CD20, Her2, PD-L1, and FLT-3.